Clinical Trials Browser

Non-Muscle Invasive Bladder Neoplasms

NCT05796375 2026-01-30

ReplaceCysto

Phase 2 Recruiting

240 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Neoplasms

NCT05951179 2026-01-27

ADVANCED-2

Phase 2 Recruiting

131 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT06733363 2026-01-27

A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer

Phase 2 Recruiting

344 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT07283835 2026-01-21

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Phase 2 Recruiting

16 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ

NCT05327647 2025-12-18

BicaBCa

Phase 2 Recruiting

160 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT03945162 2025-11-24

Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

Phase 2 Recruiting

90 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06663137 2025-06-13

HGNMIBC

Phase 2 Recruiting

70 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT07019220 2025-06-13

COBRA

Phase 2 Recruiting

47 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Neoplasms

NCT04375813 2025-05-15

eRapa

Phase 2 Recruiting

166 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06187506 2024-07-12

Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer

Phase 2 Recruiting

20 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT03379909 2023-09-21

TROJAN

Phase 2 Recruiting

49 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT05957757 2023-08-31

RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression

Phase 2 Recruiting

20 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT05943379 2023-07-13

RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects

Phase 2 Recruiting

85 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

Clinical Trials

SURF302

ReplaceCysto

ADVANCED-2

A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

BicaBCa

Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

HGNMIBC

COBRA

eRapa

Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer

TROJAN

RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression

RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects